Trials / Recruiting
RecruitingNCT06541860
DAratumumab and REvlimid REfractory MM
Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
Conditions
Timeline
- Start date
- 2023-08-21
- Primary completion
- 2028-02-21
- Completion
- 2028-08-21
- First posted
- 2024-08-07
- Last updated
- 2024-08-07
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06541860. Inclusion in this directory is not an endorsement.